-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H8nfilR0QlUB20wBZgfb/qONLDZcIN+Q3d3fa+3+DhCdZcRQrCpH3l9NUWvD4jtX 803ZO5HwPIw2wX2H2VfZaw== 0000891020-03-002224.txt : 20030821 0000891020-03-002224.hdr.sgml : 20030821 20030821115714 ACCESSION NUMBER: 0000891020-03-002224 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20030821 ITEM INFORMATION: ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARGETED GENETICS CORP /WA/ CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 03859452 BUSINESS ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 2066237612 MAIL ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 8-K 1 v92650e8vk.htm FORM 8-K Targeted Genetics Corporation Form 8-K
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 21, 2003

Targeted Genetics Corporation


(Exact name of registrant as specified in charter)
         
Washington   0-23930   91-1549568

(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
     
1100 Olive Way, Suite 100, Seattle, Washington   98101

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (206) 623-7612

Not Applicable


(Former name or former address, if changed since last report)

1


Item 7. Exhibits.
Item 12. Results and Operations of Financial Condition.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

Item 7. Exhibits.

  (a)   Financial statements of business acquired.
 
      Not applicable.
 
  (b)   Pro forma financial information.
 
      Not applicable.
 
  (c)   Exhibits.

     
Exhibit    
No.   Description

 
99.1   Press Release of Targeted Genetics Corporation dated August 21, 2003

Item 12. Results and Operations of Financial Condition.

     On August 21, 2003, Targeted Genetics Corporation issued a press release announcing the effectiveness of its registration statement on Form S-3. A copy of the press release is furnished as Exhibit 99.1 and is incorporated into this current report by reference.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    TARGETED GENETICS CORPORATION
         
         
Date: August 21, 2003   By:   /s/ H. STEWART PARKER
H. Stewart Parker
President and Chief Executive Officer
(Principal Executive Officer)

 


Table of Contents

EXHIBIT INDEX

     
Exhibit    
No.   Description

 
99.1   Press Release of Targeted Genetics Corporation dated August 21, 2003

  EX-99.1 3 v92650exv99w1.htm EXHIBIT 99.1 exv99w1

 

Exhibit 99. 1

(TARGETED GENETICS LOGO)  ®

Contact:
Targeted Genetics Corporation
Courtney Self
(206) 521-7392

TARGETED GENETICS ANNOUNCES EFFECTIVENESS
OF ITS SHELF REGISTRATION STATEMENT

Seattle, WA— August 21, 2003—Targeted Genetics Corporation (Nasdaq: TGEN) announced today that its shelf registration statement on Form S-3 filed on August 11, 2003, has been declared effective by the U.S. Securities and Exchange Commission (SEC). The shelf registration for the sale of up to 11,600,000 shares of its common stock will allow Targeted Genetics to sell common stock from time to time in one or more offerings at its discretion. The shelf registration is intended to provide flexibility in financing the Company’s business objectives going forward. Specific terms of any issuance of common stock under this shelf registration would be established at the time of sale.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the prospectus included in the registration statement is available in the Investor Relations section of the Targeted Genetics website at www.targetedgenetics.com, the SEC’s website at www.sec.gov, or via written request to Targeted Genetics Corporation, 1100 Olive Way, Suite 100, Seattle, Washington 98101, Attention: Investor Relations. In addition, Targeted Genetics will file a prospectus supplement with the SEC in connection with any offering under the shelf registration statement.

Targeted Genetics develops gene therapy products for treating acquired and inherited diseases. The Company has a lead clinical product development program targeting cystic fibrosis and a

 


 

promising pipeline of product candidates focused on arthritis, an AIDS vaccine, hemophilia and cancer. The Company has a broad platform of gene delivery technologies as well as a promising body of technology for cellular therapy. For more information about Targeted Genetics Corporation, please visit the Company’s web site at http://www.targetedgenetics.com.

NOTE: This release contains forward-looking statements regarding offerings of our common stock in the future, which are based on opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by these forward-looking statements. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of these forward-looking statements. Factors that could affect our actual results include, but are not limited to, market conditions that prevent us from commencing or completing an offering on acceptable terms, if at all, changes in our financing plan, changes in our business, as well as the other risk factors described in the section entitled “Factors Affecting Our Operating Results, Our Business and Our Stock Price” included in our report on Form 10-Q for the quarter ended June 30, 2003. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to reflect new information, circumstances or events after the date of this release or to reflect the occurrence of unanticipated events.

###

  GRAPHIC 4 v92650v9265000.gif GRAPHIC begin 644 v92650v9265000.gif M1TE&.#EAB@"\`/<```!:2@!C2@!C4@!K4@!K6@!S6@!S8P![8P![:P"$:PA[ M:PB$:PB$QB,R&$RF$RF,A"F4A#&, MS&4A#&4C#F,>SF4>SF4A#F4C#FUKW6 MSKW6UKW>UKW>WL;6UL;>UL;>WL;GWL[>UL[>WL[GWL[GY];GWM;GY];OY][G MY][OY][O[^?O[^?W[^?W]^_O[^_W[^_W]_?W]_?_]_?_________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________RP`````B@"\```(_@#_"!Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DR@17F'BA*7+EC!?RHQ)--Y@(`1")@8.'%:PX;7!'PT.,U@A1C0$ MY08,$!A1,,N`[`BR_@]H4O!(]O,%JA,T$SY[@Q"T'=I^Z&6[0CKA%R!,8V## MD2,C$+#!02<,0`%>%PR@'D$;'"#$$4,(X41!9=APQ`H%D,"$#5D4)(8!'_PW MQ`]J%&2'`P[\]P$!"_#QT'P.94$`"`I=0<`)Z1UDA@$_#.0``@:9(>!`<9!G MT`5`,N3%`%(@%$8!1RADQP(#"O0#`3W*QQ9$611`8T+$Q5'`E@.9,28?>UQA MP`,&V3"`%W^X""8"89B1!1T):3$`$TX:,)08%,8!_@2< MRIU!4R8Z``1R*DIFC`0X>A`38V9A`0$+EMD?$0\8D,9!*!!0(@P'P`J#01L@ MH`8=7L1G$*M]VD`''%ILQD"A?!!@P8N[,MHKF`8@@,`"!I@0I`$Z_'&%`"P< ME(4`*_Q161@$[$!MD@MY-Z&K!`@A)94#73'`M%I.U"A"=A!PEA\/,*#M'SO6 M^T>RJAKD0`$GN/&&"01`S"`"91BEQA5['*1GJP:%80`,H(D1AHD,4*!&&CMD MAV?$$ATQP`-^'/1#`#L+!(,`5G0G`,3W?K"9!0,,0)@#)1*TQP,%:*UU`3$; M=$0`66Y;6-:GDAD'K%H3<,"FZ$YD1AIBE%V0_AEFH/9'470/]'.@%$2B19KC,>-U_A>[1HJ*73A'IIJ<.ND-\ MM.[ZZ[#'+OOLM-=N^^VXW]X'1*C73($-,,0@0_##"T_\\<8G7_SRR#.O?//0 M/R^]\]1'7[T-_JW.D)VJD^5&DT0W%,85W8]E!O@-];XW^N6?E,;!Z:>+$!E3 MM)_2^]HO=+[]*.$?/D-D(-]'RG"%+!3P@`9,(`(7J$`#BL5_\7O(&*+6$3R\ MH``%T,YA-FB8#&:P@QS<8`8'<(*4[.]_"Z%?1Z1@&'>Y\(4PC*$,P\,F]\%/ M5P\YH4;HD!WE1"LY_LGQH0^#",0?"I&(#Q@:272(0X<$D"-"V$`(0##%*E:1 MBE2\HA:UB,40;.`$DP,)!)O8D`GR[R1,7(CZ"*+",Y9DC&J4GX[8Y\:0P%$A M:QS($S62!C.4@6]__*,?!SE(0082D(0\9"$1^4>_;>2.@)&C0()3WG.TY[T_KRG M///)3WA^8&,502="\B@02G;$<@1!Z!\4RM"$.G0@"MU=KBX"R8&ZDHWUJ^-( M*GH0@G),FAKM"$<-XM%U9H0/;8@#'%3*TI6ZM*4P?:E,8TI3F4YT(B,MB$<- MJA$:3"`#&=!`4(#2M8Q_K5LHK5K&/U:@6:AM-GMC*:'DE#!SJ0U;K2=:Y9O:M>\\I7 MO/IUKW^U:P4`*E6WIM.)`NS('%1`@QF\P+$S:"P-7-#8QTZVLI&E+&0ONUG- M6M:SD9V!"BPRU8'LE((>>5T?5-NZU?+!M;!M_JUL7SO;V-+6=;NK2&D%4M60 MBF2W?_"H0'V;$>"6-+$F00,6NL#\9HWO"7``D6OV]&+ZM&J)[$##5HP@QG0M[[WM6]]]8O?_>;W MOS,H01O6FS^%#%X*`' M/NAPB$$LX@^/^,0E!C$.H%!<]I+TPG_@:4KVL`)\`T=_A^*`&(@M+D';O:!FZD05RJ;%LEFELN:.8SB$0-!RE-F M\D$R7#HH/,'04$#T$Y;@R$?:F;=6UJZ2SYGG%ZLSS9.N\*.#B^=,<\3"ZG2R MIRV2Y"IG=]24%K1!AHSJ):/0P)5NM4-`C5C3V0$._GH-" M71U!AUPY+F%(0A&6701E,[O9SX9V$;B0D5+?^=*A@\,3BJ`$)3S!V^#^MKC# MW6TE)`$+-Y4(K1MB[9-P@=OFCK>\D]!M>L?;WMTN0A72#9%U`U#49+%#%:B` MA8(;_.`(3_C!J="%0+\Z(<<>R[`ODEN*^#N%F)9U1"X.:XT[O-@-(31*_OA@ MAY*;_.0H3[G*4UJ_P(9//5QHB\DXB#Q@XM<)-$X_:'O>_<[WP5/>+ZW M?..;[JW'+9[X3B^^K:I^)<`]4F,H5_[&K<.\Y3,/Y?EI1X+2LYO^ M]*A//>H'#.2'S\_H.R2#W,E`^]K;_O:XSSWNO]`71T=^/5^?"!_8\`4PR)X, MQI>[W)-_?.8O__C/5S[R9=_[T`I<[#B@[@/81"8@0[K<08U=S/]=S.Y>!'+B!-4=8=M1XV#81>H!U M6G>"35<%=&=#`"@0+U<0?&!P5U=P,VB"-FB#-3B#!,<%$T<2$SAH"PA`7,`% M7<`%6$"$0VB$13B$2ZB$2=B$R_6$7/`%AR<2HA=I%>$ZE:>%KL5YL[6%:-*% MG=>#;R2":':`B->"'X6&_6:&(1>$#=%YN=,^5QAS%H$%W$9O>:@$>[AL2U"% M?O&#JP9[$/%MW6:(_DO0;8F8!%!E/X*X/B=EB/AV;^K%/W68?>SD;4^PB8>V MB97(/X]($!4($7N@!WN0!Z=XBJ#G1I<8( MC=JXC=>8C=ZH!("(1M>G>!BQ87#V9D`08ND(9^K8CB06!.%8AFKX@@G1!FTF M9_@8!'(&9^F(C?DH9W'V!'$AC2F$BP#4`F%V`UO&90NID`SYD!!I7T40C[_E MAM,H:22(BGE@BJBH!QWYD:4(DAY9BAQ)D2%!D`K!:L88BQ:I/[1X@,AH_I"Y MB)(0AY$/X08M`&9=II-AYF4]N9,[^9-""68S@`,@^'^_B%$4H0""9AX60)%L$3CB(45 MD04(9P4'!YD&)YD%1YE88)F8&9E6IT1BU)(I&8R]2(ST").>J8`KF1`T28$V M"1%Q4`(FX%TJ$)NP*9NQ29NU.9OB=9NUF9NV29LMX!R:IH8J*1%9D`%V=9QW MA9S*F9S,N9S*&8%M.(]C:1!+H`'.V9S8>9W:_LF<)7"4$)&:0*@115`">:E@ MYLF7YYF>Z+F>ZMF>Z!F;):`"T-D0Q$B-#.$'=C"2&XF*^:F1(]F?JLB?^OF? M`RJ@_JF1=C"?#(&,H)F+HCF=BQ>3IXD0X#E)JWD17F`!'S`"&]JA'/JA'AJB M(#JB(EJB(+H""GH0#`H2(S!+WO2B,!JC,CJC!]!UT2F7+@BA%F@!#O!-VG1+ M/YI-MN2C0_JC12JD00JD1+I,&]!HA26<="D1:S`!%E"E5GJE6)JE6KJE6SHK MC+>+%YH1=E`'=%`'9'JF9&H'97JF:HJF9;JF=-"F;/JF9DJG!(:C?S"<$_J@ M$ZJBI=EDI<,'=[!Y_IA7J):W!V28AGAJGRAA!Q+0+C,T0P:@HPCXIX/6H&(A M!@.```?`J>[2J9WJJ:%Z``6P:0K!IZ:C`Y`:JI[ZJ:YZ``ZP@J2VF*&6.GQ` M`9$:0P90+&#Y5L86IFZQ!VX0!\3Z!L1:K,<:!\-J?<*)J6PHFL`JC&I@J08A M!DW`!WC`D7MP!Z5XBMG:K0EJBGJ`!QVYK:DXKMK*K1SYK:88KJ5(KMW*K1WY MK:BHKMXJKGO@KN-:KO+ZKNG:K:@8!M1:$'!@%CE@`PA;`SJ0L#:PL#6`L#KP ML`A[L`F[L#;PL`X+L1)K`Q1[L1:+L1>KL0C+L2.KL`R;L0V[L1UKLB&+_K(1 M.[(ZP`)L97=].A(>5;,8<;,X:Q$ZN[.G`V-$$@(.H``2(`38A!BDB@$`0-.BP!9P[8$\08$4`"XJC50F[0- M,0*1,K@(,04#<`1[$*=OD&Y9D!U5HAP'804$0`1Z4`=V\`:K.!!UH`9VL",G M4'(S*Q!OXZ4$82,7$*=GP`#J)Q#-LC-\8`,Q_L`[,,8'[<(8G'F[!-`A"C&[ M#D``36*[5TL`!ODV_8(0R7L0%&``?A,X#((EKY&BD/80>W`TFM$$#``"'[`! M`E,04R"Z(+`!@KN\!.`%[?('EM*X!C`!(7`!!TRP?I(0[6L0!$`!%=\`B>,($A`$K3FH%AT$``2`_WM$&1$``1Q`>#HP8`E`#"O$&%)WC3L`F_*^-'R^ MT?H'<;##!W'!!:$`"!`?PK$0P'(!:O@'4I!!=$,'$)`J!H&[VB6[`U`&?Z#` MYEL0N,L^9`@'7FRY_CU\$#9``#@L$!3`>I_KN70P)'@J$`%"`!)0+88AOP)A M(QBP`BMP`B,@3=YAQY]R&/I"`!>`R2NP`6;6Q>O[Q8%L$'G`N1^@`Q`P`!)@ M$",P`!L0LYR[.32K)!>`(A2`H@%G_),SR`XS_5,$"8':/-9Q'T19=T1CM>9JWT9W'T1>MT1T=TA_MT1E-TB`]TE#V20 -----END PRIVACY-ENHANCED MESSAGE-----